Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial.

ABSTRACT:

Background

The aim of this study was to evaluate whether Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification could predict mortality risk factors and whether baseline treatment intensity would relate to mortality within each group, using data from TIOSPIR(®), the largest randomized clinical trial in COPD performed to date.

Methods

A total of 17,135 patients from TIOSPIR(®) were pooled and grouped by GOLD grading (A-D) according to baseline Medical Research Council breathlessness score, exacerbation history, and spirometry. All-cause mortality and adjudicated cardiovascular (CV) and respiratory mortality were assessed.

Results

Of the 16,326 patients classified, 1,248 died on treatment. Group B patients received proportionally more CV treatment

SUBMITTER: Dusser D 

PROVIDER: S-EPMC4725639 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature